GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarti Drugs Ltd (BOM:524348) » Definitions » Buyback Yield %

Aarti Drugs (BOM:524348) Buyback Yield % : 0.00 (As of Dec. 12, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Aarti Drugs Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Aarti Drugs's current buyback yield was 0.00%.


Aarti Drugs Buyback Yield % Historical Data

The historical data trend for Aarti Drugs's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarti Drugs Buyback Yield % Chart

Aarti Drugs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.15 - 1.51 -0.02 1.50

Aarti Drugs Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aarti Drugs's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Drugs's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Aarti Drugs's Buyback Yield % falls into.



Aarti Drugs Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Aarti Drugs's Buyback Yield for the fiscal year that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-598.5 + 0) / 39885.99975
=1.50%

Aarti Drugs's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 46826.0735
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Sep. 2024) data.


Aarti Drugs Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Aarti Drugs's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aarti Drugs Business Description

Traded in Other Exchanges
Address
Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.

Aarti Drugs Headlines

No Headlines